Fig. 5.

Effect of Ara-C/the AurA inhibitor co-treatment on primary AML cells and normal hematopoietic cells, and effect of G-CSF priming on this co-treatment. Primary leukemia cells from patients were treated with Ara-C (1 µM)±the AurA inhibitor (2 µM) for 48 h. (A) Cells were evaluated for apoptosis by flow cytometry in total cells, CD34⁺/CD38^- cells, and CD34⁺/CD38⁺ cells, and compared to normal CD34⁺ hematopoietic stem cells. Bars indicate SD. (B) Primary CD34⁺/CD38^- cells containing LSCs were stimulated with G-CSF (1 µg/mL) for 7 days and analyzed for expression of AurA. Bars indicate SD. (C) CD34⁺/CD38^- cells were stimulated with G-CSF for 7 days and then treated with or without Ara-C and the AurA inhibitor. Evaluation of apoptosis was performed by flow cytometry. Bars indicate SD.